Methyprednisolone can be injected intraarticularly to relieve pain associated with osteoarthritis. It can also administered systemically to reduce the frequency and severity of infusion reactions prior to infusion of certain medications like rituximab for rheumatoid arthritis.
The FDA is currently reporting a shortage in certain strengths and presentations of Solu-Medrol Powder for Injection (Pfizer) and the generic Methylprednisolone sodium succinate for injection (Fresenius Kabi).
Specifically, Pfizer will be sending weekly shipments of Solu-Medrol Sterile Powder for Injection 40mg/single-use vial and 125mg/single-use vial ACT-O-Vial System while the product is in shortage, with full recovery projected at the beginning of July 2016. Other strengths and presentations of Solu-Medrol are currently available.
Fresenius Kabi is reporting that Methylprednisolone sodium succinate for injection 40mg single-dose vial and 125mg single-dose vial are both on backorder with the next release of product expected in late April 2016.; the 1g single-dose vial is currently available.
Solu-Medrol is indicated for the treatment of steroid-responsive disorders when oral therapy may not be feasible.
For more information visit FDA.gov.
This article originally appeared on MPR